secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2023-01-10T23:59:59+00:00
Accession:  0001437749-23-000801
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pieris receives $5M milestone from Seagen for Phase 1 start of CD228 x 4-1BB bispecific SGN-BB228
--------------------------------------------------------------------------------

- Achieved $5M milestone from Seagen upon first patient dosed in Phase 1 study of SGN-BB228 (PRS-346).
- Phase 1 trial (NCT05571839) evaluates SGN-BB228 in advanced melanoma and other solid tumors.
- This is the first clinical start in Pieris' collaboration with Seagen; two additional programs ongoing.
- Pieris has an opt-in option for U.S. co-promotion on one program in the collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000143774923000801/0001437749-23-000801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000143774923000801/pirs20230110c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-000801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer